Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with thiazolidinedione with an extension treatment for up to 52 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo / Teneli + Pio | Placebo Comparator |
| |
| Teneli / Teneli + pio | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo / Teneli (Teneligliptin) + pio (pioglitazone) | Drug | Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in HbA1c at Week 12 | The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate. | at Week 0 and Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 12 | The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate. | at Week 0 and Week 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Takashi Kadowaki, Professor | Tokyo University | Study Director |
| Kazuoki Kondo, MD | Tanabe Pharma Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shinjukuku | Tokyo | Japan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24843712 | Derived | Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013 Nov 27;4(6):576-84. doi: 10.1111/jdi.12092. Epub 2013 May 27. | |
| 24205974 | Derived | Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014 May;16(5):418-25. doi: 10.1111/dom.12235. Epub 2013 Dec 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo/Teneli + Pio | Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
| FG001 | Teneli/Teneli + Pio | Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period 1：Double Blind Period |
|
| |||||||||||||||||||||
| Period 2：Open-label Period |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo/Teneli + Pio | Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
| BG001 | Teneli/Teneli + Pio |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in HbA1c at Week 12 | The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate. | The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. Analysis based on last observation carried forward, where the last postbaseline double-blind observed value was carried forward and used for Week 12 where data was missing. | Posted | Least Squares Mean | Standard Error | Percent of HbA1c | at Week 0 and Week 12 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo/Teneli + Pio (Data Through Week 12) | Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. The adverse events which occured from Week 0 to Week 12 were shown. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abscess | Infections and infestations |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trials, Information Desk | Tanabe Pharma Corporation | cti-inq-ml.JP@ml.tanabe-pharma.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C579035 | 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine |
| D010389 | Pemoline |
| D000077205 | Pioglitazone |
| ID | Term |
|---|---|
| D010080 | Oxazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Teneli / Teneli + pio | Drug | Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
|
| Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12 |
The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate. |
| 0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12 |
| Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12 | The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate. | at Week 0 and Week 12 |
| Physician Decision |
|
| NOT COMPLETED |
|
|
Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Teneli/Teneli + Pio | Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. |
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose at Week 12 | The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate. | The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. Analysis based on last observation carried forward, where the last postbaseline double-blind observed value was carried forward and used for Week 12 where data was missing. | Posted | Least Squares Mean | Standard Error | mg / dL | at Week 0 and Week 12 |
|
|
|
| Secondary | Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12 | The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate. | The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. | Posted | Least Squares Mean | Standard Error | mg*h / dL | 0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12 |
|
|
|
| Secondary | Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12 | The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate. | The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. | Posted | Least Squares Mean | Standard Error | mg / dL | at Week 0 and Week 12 |
|
|
|
| 1 |
| 101 |
| 47 |
| 101 |
| EG001 | Teneli/Teneli + Pio (Data Through Week 12) | Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. The adverse events which occured from Week 0 to Week 12 were shown. | 4 | 103 | 63 | 103 |
| EG002 | Placebo/Teneli + Pio (Data From Week 12 to Week 52) | Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. The adverse events which occured from Week 12 to Week 52 were shown. | 3 | 98 | 89 | 98 |
| EG003 | Teneli/Teneli + Pio (Data Through Week 52) | Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone. The adverse events which occured from Week 12 to Week 52 were shown. | 11 | 103 | 88 | 103 |
| Metastases to bone | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
|
| Oesophageal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
|
| Large intestine carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
|
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 13.1 |
|
| Loss of consciousness | Nervous system disorders | MedDRA ver. 13.1 |
|
| Carotid artery stenosis | Nervous system disorders | MedDRA ver. 13.1 |
|
| Myelopathy | Nervous system disorders | MedDRA ver. 13.1 |
|
| Cataract | Eye disorders | MedDRA ver. 13.1 |
|
| Acute myocardial infarction | Cardiac disorders | MedDRA ver. 13.1 |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA ver. 13.1 |
|
| Colonic polyp | Gastrointestinal disorders | MedDRA ver. 13.1 |
|
| Gastric polyps | Gastrointestinal disorders | MedDRA ver. 13.1 |
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA ver. 13.1 |
|
| Acute tonsillitis | Infections and infestations |
|
| Bronchitis | Infections and infestations |
|
| Cystitis | Infections and infestations |
|
| Nasal abscess | Infections and infestations |
|
| Nasopharyngitis | Infections and infestations |
|
| Pharyngitis | Infections and infestations |
|
| Pneumonia | Infections and infestations |
|
| Tonsillitis | Infections and infestations |
|
| Gastritis viral | Infections and infestations |
|
| Herpes dermatitis | Infections and infestations |
|
| Oral herpes | Infections and infestations |
|
| Folliculitis | Infections and infestations |
|
| Gastroenteritis | Infections and infestations |
|
| Herpes simplex | Infections and infestations |
|
| Hordeolum | Infections and infestations |
|
| Influenza | Infections and infestations |
|
| Laryngitis | Infections and infestations |
|
| Oesophageal candidiasis | Infections and infestations |
|
| Onychomycosis | Infections and infestations |
|
| Otitis externa | Infections and infestations |
|
| Paronychia | Infections and infestations |
|
| Parotitis | Infections and infestations |
|
| Rhinitis | Infections and infestations |
|
| Sinusitis | Infections and infestations |
|
| Tinea pedis | Infections and infestations |
|
| Urethritis | Infections and infestations |
|
| Gingival abscess | Infections and infestations |
|
| Helicobacter infection | Infections and infestations |
|
| Tinea versicolour | Infections and infestations |
|
| Bone abscess | Infections and infestations |
|
| Thyroid neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Ovarian neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Iron deficiency anaemia | Blood and lymphatic system disorders |
|
| Leukopenia | Blood and lymphatic system disorders |
|
| Seasonal allergy | Immune system disorders |
|
| Hypoglycaemia | Metabolism and nutrition disorders |
|
| Hyperphosphatasaemia | Metabolism and nutrition disorders |
|
| Dehydration | Metabolism and nutrition disorders |
|
| Gout | Metabolism and nutrition disorders |
|
| Hyperuricaemia | Metabolism and nutrition disorders |
|
| Hyperlipidaemia | Metabolism and nutrition disorders |
|
| Insomnia | Psychiatric disorders |
|
| Cervicobrachial syndrome | Nervous system disorders |
|
| Dizziness | Nervous system disorders |
|
| Headache | Nervous system disorders |
|
| Hypoaesthesia | Nervous system disorders |
|
| Neuralgia | Nervous system disorders |
|
| Tension headache | Nervous system disorders |
|
| Lacunar infarction | Nervous system disorders |
|
| Spinocerebellar disorder | Nervous system disorders |
|
| Cerebrovascular stenosis | Nervous system disorders |
|
| Carotid artery stenosis | Nervous system disorders |
|
| Intercostal neuralgia | Nervous system disorders |
|
| VIIth nerve paralysis | Nervous system disorders |
|
| Carotid arteriosclerosis | Nervous system disorders |
|
| Occipital neuralgia | Nervous system disorders |
|
| Conjunctivitis | Eye disorders |
|
| Blepharitis | Eye disorders |
|
| Cataract | Eye disorders |
|
| Conjunctival haemorrhage | Eye disorders |
|
| Conjunctivitis allergic | Eye disorders |
|
| Corneal opacity | Eye disorders |
|
| Diabetic retinopathy | Eye disorders |
|
| Dry eye | Eye disorders |
|
| Eyelid oedema | Eye disorders |
|
| Glaucoma | Eye disorders |
|
| Keratoconjunctivitis sicca | Eye disorders |
|
| Retinal vein occlusion | Eye disorders |
|
| Vision blurred | Eye disorders |
|
| Meibomian gland dysfunction | Eye disorders |
|
| Vertigo | Ear and labyrinth disorders |
|
| Bundle branch block left | Cardiac disorders |
|
| Cardiomegaly | Cardiac disorders |
|
| Atrial fibrillation | Cardiac disorders |
|
| Palpitations | Cardiac disorders |
|
| Cardiac valve disease | Cardiac disorders |
|
| Hypertension | Vascular disorders |
|
| Hypotension | Vascular disorders |
|
| Cough | Respiratory, thoracic and mediastinal disorders |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders |
|
| Oropharyngeal discomfort | Respiratory, thoracic and mediastinal disorders |
|
| Asthma | Respiratory, thoracic and mediastinal disorders |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders |
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders |
|
| Abdominal discomfort | Gastrointestinal disorders |
|
| Abdominal distension | Gastrointestinal disorders |
|
| Abdominal pain upper | Gastrointestinal disorders |
|
| Anal fissure | Gastrointestinal disorders |
|
| Cheilitis | Gastrointestinal disorders |
|
| Colonic polyp | Gastrointestinal disorders |
|
| Constipation | Gastrointestinal disorders |
|
| Dental caries | Gastrointestinal disorders |
|
| Diarrhoea | Gastrointestinal disorders |
|
| Gastric polyps | Gastrointestinal disorders |
|
| Gastritis | Gastrointestinal disorders |
|
| Gingival swelling | Gastrointestinal disorders |
|
| Reflux oesophagitis | Gastrointestinal disorders |
|
| Stomatitis | Gastrointestinal disorders |
|
| Gastric xanthoma | Gastrointestinal disorders |
|
| Abdominal pain lower | Gastrointestinal disorders |
|
| Duodenal ulcer | Gastrointestinal disorders |
|
| Enterocolitis | Gastrointestinal disorders |
|
| Flatulence | Gastrointestinal disorders |
|
| Gastric ulcer | Gastrointestinal disorders |
|
| Gastritis atrophic | Gastrointestinal disorders |
|
| Gastritis erosive | Gastrointestinal disorders |
|
| Gingivitis | Gastrointestinal disorders |
|
| Haemorrhoids | Gastrointestinal disorders |
|
| Nausea | Gastrointestinal disorders |
|
| Periodontal disease | Gastrointestinal disorders |
|
| Periodontitis | Gastrointestinal disorders |
|
| Supernumerary teeth | Gastrointestinal disorders |
|
| Vomiting | Gastrointestinal disorders |
|
| Gastric mucosal lesion | Gastrointestinal disorders |
|
| Erosive oesophagitis | Gastrointestinal disorders |
|
| Hepatic steatosis | Hepatobiliary disorders |
|
| Cholelithiasis | Hepatobiliary disorders |
|
| Hepatic congestion | Hepatobiliary disorders |
|
| Hyperplastic cholecystopathy | Hepatobiliary disorders |
|
| Acne | Skin and subcutaneous tissue disorders |
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders |
|
| Dry skin | Skin and subcutaneous tissue disorders |
|
| Eczema | Skin and subcutaneous tissue disorders |
|
| Eczema asteatotic | Skin and subcutaneous tissue disorders |
|
| Heat rash | Skin and subcutaneous tissue disorders |
|
| Ingrowing nail | Skin and subcutaneous tissue disorders |
|
| Pruritus | Skin and subcutaneous tissue disorders |
|
| Rash | Skin and subcutaneous tissue disorders |
|
| Skin exfoliation | Skin and subcutaneous tissue disorders |
|
| Urticaria | Skin and subcutaneous tissue disorders |
|
| Dandruff | Skin and subcutaneous tissue disorders |
|
| Dermatitis atopic | Skin and subcutaneous tissue disorders |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders |
|
| Eczema nummular | Skin and subcutaneous tissue disorders |
|
| Pityriasis rosea | Skin and subcutaneous tissue disorders |
|
| Seborrhoeic dermatitis | Skin and subcutaneous tissue disorders |
|
| Xeroderma | Skin and subcutaneous tissue disorders |
|
| Photodermatosis | Skin and subcutaneous tissue disorders |
|
| Hyperkeratosis palmaris and plantaris | Skin and subcutaneous tissue disorders |
|
| Arthralgia | Musculoskeletal and connective tissue disorders |
|
| Back pain | Musculoskeletal and connective tissue disorders |
|
| Haemarthrosis | Musculoskeletal and connective tissue disorders |
|
| Muscle spasms | Musculoskeletal and connective tissue disorders |
|
| Myalgia | Musculoskeletal and connective tissue disorders |
|
| Neck pain | Musculoskeletal and connective tissue disorders |
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders |
|
| Periarthritis | Musculoskeletal and connective tissue disorders |
|
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders |
|
| Tenosynovitis | Musculoskeletal and connective tissue disorders |
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders |
|
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders |
|
| Groin pain | Musculoskeletal and connective tissue disorders |
|
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders |
|
| Osteoporosis | Musculoskeletal and connective tissue disorders |
|
| Plantar fasciitis | Musculoskeletal and connective tissue disorders |
|
| Scoliosis | Musculoskeletal and connective tissue disorders |
|
| Spinal column stenosis | Musculoskeletal and connective tissue disorders |
|
| Tendonitis | Musculoskeletal and connective tissue disorders |
|
| Trigger finger | Musculoskeletal and connective tissue disorders |
|
| Spondylolisthesis | Musculoskeletal and connective tissue disorders |
|
| Nephrolithiasis | Renal and urinary disorders |
|
| Calculus urinary | Renal and urinary disorders |
|
| Dysuria | Renal and urinary disorders |
|
| Hypertonic bladder | Renal and urinary disorders |
|
| Nocturia | Renal and urinary disorders |
|
| Pollakiuria | Renal and urinary disorders |
|
| Diabetic nephropathy | Renal and urinary disorders |
|
| Calculus prostatic | Reproductive system and breast disorders |
|
| Erectile dysfunction | Reproductive system and breast disorders |
|
| Chest discomfort | General disorders |
|
| Oedema peripheral | General disorders |
|
| Pyrexia | General disorders |
|
| Chest pain | General disorders |
|
| Feeling abnormal | General disorders |
|
| Malaise | General disorders |
|
| Mass | General disorders |
|
| Thirst | General disorders |
|
| Blood calcium decreased | Investigations |
|
| Blood creatine phosphokinase increased | Investigations |
|
| Blood triglycerides increased | Investigations |
|
| Blood urea increased | Investigations |
|
| Blood uric acid increased | Investigations |
|
| Gamma-glutamyltransferase increased | Investigations |
|
| Glucose urine present | Investigations |
|
| Blood urine present | Investigations |
|
| White blood cell count increased | Investigations |
|
| Protein urine present | Investigations |
|
| Urine ketone body present | Investigations |
|
| Occult blood positive | Investigations |
|
| Animal bite | Injury, poisoning and procedural complications |
|
| Joint sprain | Injury, poisoning and procedural complications |
|
| Scratch | Injury, poisoning and procedural complications |
|
| Thoracic vertebral fracture | Injury, poisoning and procedural complications |
|
| Contusion | Injury, poisoning and procedural complications |
|
| Post procedural complication | Injury, poisoning and procedural complications |
|
| Open wound | Injury, poisoning and procedural complications |
|
| Arthropod sting | Injury, poisoning and procedural complications |
|
| Bite | Injury, poisoning and procedural complications |
|
| Nail avulsion | Injury, poisoning and procedural complications |
|
| Radius fracture | Injury, poisoning and procedural complications |
|
| Excoriation | Injury, poisoning and procedural complications |
|
| Iliotibial band syndrome | Injury, poisoning and procedural complications |
|
| Heat illness | Injury, poisoning and procedural complications |
|
Not provided
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |
| D045162 |
| Thiazolidinediones |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |